ArticlePloS one2026
Skin manifestations of primary COVID-19 infection with the omicron variant.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Occupational Contact Dermatitis in the Post-COVID Era: From Barrier Dysfunction and Microbiome Dysbiosis to Prevention and Precision Management.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough cutaneous manifestations of COVID-19 have been increasingly documented across earlier variants, the dermatological characteristics specifically associated with the Omicron variant, particularly in the Chinese population, remain insufficiently characterized in the literature.
objectiveTo characterize cutaneous manifestations in patients with primary COVID-19 infection caused by the Omicron variant and corresponding management.
methods94 participants were included in this retrospective analysis, who developed dermatologic symptoms within one month of COVID-19 Omicron Variant infection.
resultsMean age was 38 years old, ranging from 7 to 89; with 66% aged within 25-50. A significantly higher incidence of skin manifestations was reported among females (males vs. females, 1:2.76, p = 0.001). Skin rashes typically appeared three days after the onset of COVID symptoms (ranging between 2-7 days), which were mostly mild to moderate. Common morphological types included wheals, erythema, and papular/papulovesicular eruptions. Generalized rashes occurred in 50% of cases, while localized rashes mainly affected the extremities. Pruritus was the most frequent symptom (>90%), particularly in patients presenting with wheals. Clinical management included topical steroid creams and antiviral treatment for COVID-19. No follow-ups were required for most participants (>95%).
conclusionSkin rashes associated with Omicron variant COVID-19 infection, predominantly affecting young and middle-aged women, are characterized by wheals, erythema, and papular/papulovesicular eruptions. Early identification and management of these cutaneous symptoms should be integrated in the overall treatment plan of Omicron variant COVID-19 infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.